Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate plus exemestane in HR+ HER2- metastatic breast cancer refractory to non-steroidal AI
ChiCTR-OIC-17010440Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and exemestane in breast cancer, sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: progression-free survival. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
Rivoceranibexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OIC-17010440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17010440.